Dosimetric consequences of intrafraction prostate motion in scanned ion beam radiotherapy - Abstract

BACKGROUND AND PURPOSE: Scanned-beam interplay with the intrafraction target motion may result in dose deterioration in particle therapy.

The magnitude of this effect and the possibilities to mitigate it were investigated for carbon ion prostate treatments.

METHODS AND MATERIALS: For 12 prostate cases, 9 carbon ion treatment plans were prepared using 3 scanned-beam settings (spot sizes of 6, 7 and 9mm and, respectively, raster pitches of 2, 2 and 3mm) for 3 planning margins (3, 6 and 9mm). Plans were recomputed in presence of 5 intrafraction prostate motion scenarios with and without intra-beam motion compensation.

RESULTS: For 6mm margin and 7mm spot, the median (max) CTV D95% change was -0.2 (-2.6) pp (percentual points) with pure drift motion, -3.8 (-6.0) pp and -2.8 (-3.1) pp in transient motion scenarios and -4.8 (-7.7) pp and -1.8 (-5.7) pp in mixed motion scenarios. No particular raster setting brought distinct advantage, while planning margin expansion showed statistically significant effects for drift-dominated scenarios. Intra-beam motion compensation yielded improved CTV coverage.

CONCLUSION: Intrafraction prostate motion can lead to marked target coverage deterioration, dependent on individual motion patterns, which can be only partially avoided through planning-time countermeasures. Among possible delivery-time countermeasures, intra-beam motion compensation is capable of improving target coverage.

Written by:
Ammazzalorso F, Graef S, Weber U, Wittig A, Engenhart-Cabillic R, Jelen U.   Are you the author?
Department of Radiotherapy and Radiation Oncology, University of Marburg, Germany; Department of Medical Physics in Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Radiotherapy and Radiation Oncology, University of Marburg, Germany.  

Reference: Radiother Oncol. 2014 May 12. pii: S0167-8140(14)00165-0.
doi: 10.1016/j.radonc.2014.03.022


PubMed Abstract
PMID: 24833557

UroToday.com Prostate Cancer Section